January 2002
Worldwide Biotech;Jan2002, Vol. 14 Issue 1, p1
Trade Publication
Reports that the European Union Committee for Proprietary Medicinal Products has recommended marketing authorization for Kineret, a drug manufactured by Amgen company for the treatment of the signs and symptoms of rheumatoid arthritis.


Related Articles

  • Hydroxychloroquine merits a trial in early rheumatoid arthritis.  // Modern Medicine;May94, Vol. 62 Issue 5, p59 

    Presents an abstract of the article entitled, `Hydroxychloroquine compared with placebo in rheumatoid arthritis: A randomized controlled trial,' by P. Clark, E. Casas, P. Tugwell et al as published in the periodical `Annals of Internal Medicine' dated December 1, 1993.

  • Second-line arthritis drugs are safe to use as long as they keep working.  // Modern Medicine;May96, Vol. 64 Issue 5, p45 

    Presents an abstract of the article `Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis,' by S. ten Wolde et al., published in `Lancet' journal on February 10, 1996.

  • Arthritis: Fixed-combination treatment prevents NSAID-induced ulcers.  // Modern Medicine;Dec96, Vol. 64 Issue 12, p23 

    Cites studies on drug-combination treatment for arthritis presented at the 1996 symposium of the European League Against Rheumatism. Safety and efficacy of a fixed combination of the nonsteroidal anti-inflammatory drug diclofenac and the prostaglandin misoprostol; Evaluation of quality of life...

  • Early minocycline is effective for rheumatoid arthritis.  // Modern Medicine;Aug97, Vol. 65 Issue 8, p56 

    Presents an abstract of `Treatment of Early Rheumatoid Arthritis with Minocycline or Placebo: Results of a Randomized, Double-Blind, Placebo-Controlled Trial,' by J.R. O'Dell, C.E. Haire, et al from `Arthritis Rheumatology' dated May 1997.

  • Rheumatoid arthritis: Status of drug therapies. Moncur, Carolee; Williams, H. James // Physical Therapy;Jun1995, Vol. 75 Issue 6, p61 

    Describes the current drug therapies used to manage rheumatoid arthritis (RA). Brief description of the pathology, pathogenesis, and features of RA; General approach to prescribing medication; Attributes of non-steroidal anti-inflammatory drugs, corticosteroids, anti-rheumatic drugs and...

  • Disease modifying drugs in rheumatoid arthritis. Wollheim, Frank A. // BMJ: British Medical Journal (International Edition);3/15/97, Vol. 314 Issue 7083, p766 

    Editorial. Examines the effectiveness of disease modifying drugs in rheumatoid arthritis. Symptomatology of rheumatoid arthritis; Support for early aggressive treatment based on results of an open randomized study of very early cases in the Netherlands; Appropriateness of early aggressive...

  • It's all in the timing. Morrow, Shelly // Arthritis Today;Sep/Oct96, Vol. 10 Issue 5, p13 

    Discusses the health benefits of timing medications among arthritics. Findings of a study on timing medications; Late afternoon as the optimal time of taking antiarthritic medication.

  • Prolonged use of second-line drugs in rheumatoid arthritis.  // American Family Physician;6/1/1996, Vol. 53 Issue 8, p2657 

    Reports on a study by S. Ten Wolde, et al, published in the `Lancet' which assessed the effect of stopping second-line drug therapy in patients with rheumatoid arthritis. Cumulative rate of disease flare of the different protocols; Continued effectiveness in the event of an initial good...

  • Arthritis: Methotrexate dosage can be scaled down for some patients.  // Modern Medicine;Sep95, Vol. 63 Issue 9, p46 

    Presents an abstract of the report `Every-other-week methotrexate in patients with rheumatoid arthritis,' by J.M. Kremer et. al. published on the May 1995 issue of `Arthritis Rheumatology'.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics